Pharsight

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648048	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8633162	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US9248191	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8685930	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8629111	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8642556	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8292129	ALLERGAN	Dispensing device	Feb, 2031 (8 years from now)
US8561859	ALLERGAN	Dispensing device	Apr, 2032 (9 years from now)
US9676525	ALLERGAN	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	Feb, 2034 (11 years from now)
US9669974	ALLERGAN	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	May, 2034 (11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

Strength	Dosage	Availability
0.05%	EMULSION;OPHTHALMIC	Prescription

availability in other generic markets.

Click on the highlighted region to filter.